Alzamend Neuro reports Q2 fiscal 2025: cash $4.1M, equity $3.8M, five Phase II trials planned in 2025

Alzamend Neuro, Inc.

2024-Q2 EPS reported -$1.11

Net cash from financing $8.3M for six months ended Oct 31, 2024; stockholder equity improved to $3.8M from a $2.6M deficit.
Cash increased to $4.1M from $0.4M; total liabilities reduced to $1.3M from $3.2M at April 30, 2024.
Regained Nasdaq compliance; entered $25M preferred stock/warrant agreement and $6.5M ATM facility.
AL001 (lithium cocrystal) to initiate five Phase II trials in 2025 with Mass General for Alzheimer's, BD, MDD, PTSD.
ALZN002 immunotherapy trial resumption planned for 2025 after re-engaging a new CRO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.